<DOC>
	<DOC>NCT01795677</DOC>
	<brief_summary>JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with primary or secondary myelofibrosis : a prospective phase II</brief_summary>
	<brief_title>JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis</brief_title>
	<detailed_description>JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with primary or secondary myelofibrosis</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Age between 18 and 69 years No comorbidity contraindicating the transplantation : Severe respiratory failure defined as dyspnea grade III or more Severe cardiac failure defined as EF &lt; or = 30% Severe renal failure defined as creatinine clearance &lt; 30 ml/min or dialysis Dementia or nonability to give informed consent for the protocol Major alteration of performance status defined as ECOG &gt; 2 Severe liver disease defined as a cirrhosis or bilirubin &gt; 2 x ULN, or AST/ALT &gt; 5 x ULN Primary or secondary myelofibrosis diagnosed according to WHO definition (Tefferi, et al 2007) Palpable splenomegaly or splenomegaly measured by any imagery (maximum size&gt; 15 cm by ultrasound scan, Magnetic Resonance Imaging or computer tomography) Disease if intermediate or high risk according to published criteria and summarized as follows: At least one criterion among the following: Haemoglobin &lt; 100 gr/L (unrelated to medication toxicity) Leucocytes &lt; 4 G/L (unrelated to medication toxicity) or &gt; 25 G/L Poor prognosis cytogenetics : complex karyotype, abnormalities of chromosomes 5, 7 or 17 , +8, 12p, inv(3), 11q23 Two criteria among the following criteria : General symptoms (weight lost &gt; 10% in less than 6 months, night swears, specific fever &gt; 37.5Â°C) Peripheral blastosis &gt; 1% observed at least twice Thrombocytopenia &lt; 100 G/L (unrelated to treatment toxicity) Myelofibrosis transformed into acute leukaemia with 20% blasts of more in blood or bone marrow Previous treatment with JAK2 inhibitor Thrombopenia &lt; 50 G/L Comorbidities contraindicating the transplantation Comorbidity score Sorror &gt; 3 Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>JAK2 inhibitor RUXOLITINIB</keyword>
	<keyword>Primary or secondary myelofibrosis</keyword>
</DOC>